Andrew Brohl, MD
Hematology & Oncology · Tampa, FLNPI 1609022870
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,149 of the $15,868 with a category attached, or 64.0%. Deciphera Pharmaceuticals Inc. accounts for 62.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $7,616 and has fallen 94.4% since, to $430 in 2025.
Across 28 payments — averaging $566.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Deciphera Pharmaceuticals Inc.$10K
- Bayer$3K
- EMD Serono, Inc.$2K
- Aadi Bioscience, Inc.$283
- Merck$230
- Genentech, Inc.$191
- plus $391 from 4 others
Across 81 payments — averaging $80,364 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$6.2M
- Ares Trading SA$107K
- Novartis$86K
- EMD Serono, Inc.$57K
- Eli Lilly$18K
- Pfizer$57
What the payments were for
- Consulting fees$10,14964%
- Speaking & faculty fees$4,29027%
- Travel & lodging$290%
- Food & beverage$1,3549%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Deciphera Pharmaceuticals Inc. | 7 | $9,902 |
| Bayer | 2 | $2,825 |
| EMD Serono, Inc. | 5 | $2,047 |
| Aadi Bioscience, Inc. | 3 | $283 |
| Merck | 5 | $230 |
| Genentech, Inc. | 1 | $191 |
| Genentech USA, Inc. | 1 | $139 |
| Johnson & Johnson | 1 | $126 |
| Array Biopharma Inc | 1 | $97 |
| Pfizer | 2 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,868 in reported general payments places this provider in the 70th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GleevecImatinib Mesylate | 12 | $153,259 |
| Pazopanib Hcl | 18 | $152,885 |
| Imatinib Mesylate | 18 | $28,192 |
| Levothyroxine Sodium | 20 | $146 |
| Pantoprazole Sodium | 14 | $110 |
| Methylprednisolone | 15 | $48 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Tampa
- Damian LaberTampa$753K
- Richard KimTampa$637K
- Ariel Grajales CruzTampa$625K
- Julio ChavezTampa$383K
- David SallmanTampa$285K
- Daniel Kerr IiTampa$193K
- Bijal ShahTampa$150K
- Nikesh ShahTampa$141K
- Kendra SweetTampa$139K
- Hayder SaeedTampa$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.